Literature DB >> 24551718

Voglibose: an alpha glucosidase inhibitor.

Ajay S Dabhi1, Nikita R Bhatt2, Mohit J Shah3.   

Abstract

Diabetes Mellitus (DM) is a morbid disease worldwide, with increasing incidence as time passes. It has macro-vascular and micro-vascular complications. The main cause of these complications is poorly controlled postprandial hyperglycaemia. Alpha glucosidase inhibitors, namely acarbose, voglibose and miglitol, are available for therapy. Voglibose is well tolerated and effective in comparable doses among these drugs. This article highlights the important features of voglibose.

Entities:  

Keywords:  Alpha glucosidase inhibitors (αGI); Postprandial hyperglycaemia (PPHG)

Year:  2013        PMID： 24551718      PMCID： PMC3919386          DOI： 10.7860/JCDR/2013/6373.3838

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN： 0973-709X


  24 in total

Review 1.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

Review 2.  Pneumatosis cystoides intestinalis induced by the α-glucosidase inhibitor miglitol.

Authors:  Kuniyuki Kojima; Tatsuhiro Tsujimoto; Hisao Fujii; Tomoko Morimoto; Seisaku Yoshioka; Saki Kato; Yumi Yasuhara; Shigeyuki Aizawa; Mizuho Sawai; Shiro Makutani; Koji Yamamoto; Tadao Mochi; Hiroshi Fukui
Journal:  Intern Med       Date:  2010-08-02       Impact factor: 1.271

3.  Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms.

Authors:  Tomomi Fujisawa; Hiroshi Ikegami; Kaori Inoue; Yumiko Kawabata; Toshio Ogihara
Journal:  Metabolism       Date:  2005-03       Impact factor: 8.694

4.  Relationship between gastric emptying and an alpha-glucosidase inhibitor effect on postprandial hyperglycemia in NIDDM patients.

Authors:  T Kawagishi; Y Nishizawa; H Taniwaki; S Tanaka; Y Okuno; M Inaba; E Ishimura; M Emoto; H Morii
Journal:  Diabetes Care       Date:  1997-10       Impact factor: 19.112

5.  Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.

Authors:  Keisuke Fujitaka; Hajime Otani; Fusakazu Jo; Hiromi Jo; Emiko Nomura; Masayoshi Iwasaki; Mitsushige Nishikawa; Toshiji Iwasaka
Journal:  Endocr J       Date:  2011-04-17       Impact factor: 2.349

6.  Effect of an alpha-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients.

Authors:  N Saito; H Sakai; S Suzuki; H Sekihara; Y Yajima
Journal:  J Int Med Res       Date:  1998 Oct-Nov       Impact factor: 1.671

7.  Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes.

Authors:  Kazuhisa Takami; Noriyuki Takeda; Kazuya Nakashima; Rieko Takami; Makoto Hayashi; Shigehiko Ozeki; Akiko Yamada; Yoshiaki Kokubo; Mayumi Sato; Shin-ichi Kawachi; Akihiko Sasaki; Keigo Yasuda
Journal:  Diabetes Care       Date:  2002-04       Impact factor: 19.112

8.  Novel inhibitory effect of the antidiabetic drug voglibose on melanogenesis.

Authors:  Bum-Ho Bin; Juyeon Seo; Seung Ha Yang; Eunkyung Lee; Hyunjung Choi; Kyu-Han Kim; Eun-Gyung Cho; Tae Ryong Lee
Journal:  Exp Dermatol       Date:  2013-08       Impact factor: 3.960

9.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

10.  The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial.

Authors: 
Journal:  Diabetes       Date:  1995-08       Impact factor: 9.461
View more
  18 in total

1.  Synthesis, molecular modeling and biological evaluation of aza-flavanones as α-glucosidase inhibitors.

Authors:  Sivaprasad Kasturi; Sujatha Surarapu; Chandra Chary Bathoju; Srinivas Uppalanchi; Shubham Dwivedi; Yogeeswari Perumal; Dilep Kumar Sigalapalli; Bathini Nagendra Babu; Krishna S Ethiraj; Jaya Shree Anireddy
Journal:  Medchemcomm       Date:  2017-06-14       Impact factor: 3.597

2.  Type II diabetes mellitus and obesity: Common links, existing therapeutics and future developments.

Authors:  Subhadeep Banerjee; Indrani Talukdar; Arnab Banerjee; Arnav Gupta; Advait Balaji; Raviprasad Aduri
Journal:  J Biosci       Date:  2019-12       Impact factor: 1.826

3.  Development and validation of a high-throughput online solid phase extraction - Liquid chromatography - Tandem mass spectrometry method for the detection of tetrodotoxin in human urine.

Authors:  Rebecca Coleman; Sharon W Lemire; William Bragg; Alaine Garrett; Geovannie Ojeda-Torres; Elizabeth Hamelin; Rudolph C Johnson; Jerry Thomas
Journal:  Toxicon       Date:  2016-05-19       Impact factor: 3.033

4.  Dihydroquinazolin-4(1H)-one derivatives as novel and potential leads for diabetic management.

Authors:  Oluwatoyin Babatunde; Shehryar Hameed; Uzma Salar; Sridevi Chigurupati; Abdul Wadood; Ashfaq Ur Rehman; Vijayan Venugopal; Khalid Mohammed Khan; Muhammad Taha; Shahnaz Perveen
Journal:  Mol Divers       Date:  2021-03-01       Impact factor: 2.943

5.  In silico study of garlic (Allium sativum L.)-derived compounds molecular interactions with α-glucosidase.

Authors:  Morteza Sadeghi; Mohammad Moradi; Hamid Madanchi; Behrooz Johari
Journal:  In Silico Pharmacol       Date:  2021-01-07

6.  Free radical scavenging, α-glucosidase inhibitory and anti-inflammatory constituents from Indian sedges, Cyperus scariosus R.Br and Cyperus rotundus L.

Authors:  Lavanya Kakarla; Suresh Babu Katragadda; Ashok K Tiwari; K Srigiridhar Kotamraju; K Madhusudana; D Anand Kumar; Mahendran Botlagunta
Journal:  Pharmacogn Mag       Date:  2016-07       Impact factor: 1.085

7.  Inhibition of α-Amylases by Condensed and Hydrolysable Tannins: Focus on Kinetics and Hypoglycemic Actions.

Authors:  Camila Gabriel Kato; Geferson de Almeida Gonçalves; Rosely Aparecida Peralta; Flavio Augusto Vicente Seixas; Anacharis Babeto de Sá-Nakanishi; Lívia Bracht; Jurandir Fernando Comar; Adelar Bracht; Rosane Marina Peralta
Journal:  Enzyme Res       Date:  2017-05-14

8.  Stereoselective synthesis of a 4-⍺-glucoside of valienamine and its X-ray structure in complex with Streptomyces coelicolor GlgE1-V279S.

Authors:  Anshupriya Si; Thilina D Jayasinghe; Radhika Thanvi; Donald R Ronning; Steven J Sucheck
Journal:  Sci Rep       Date:  2021-06-28       Impact factor: 4.379

9.  Utilizing the Combination of Binding Kinetics and Micro-Pharmacokinetics Link in Vitro α-Glucosidase Inhibition to in Vivo Target Occupancy.

Authors:  Guopeng Wang; Yanhua Ji; Xueyan Li; Qian Wang; Hang Gong; Baoshun Wang; Yang Liu; Yanli Pan
Journal:  Biomolecules       Date:  2019-09-16

10.  The Volatile Chemical Compositions of the Essential Oil/SPME and Enzyme Inhibitory and Radical Scavenging Activities of Solvent Extracts and the Essential oils from Coronilla orientalis Miller and C. varia L. grows in Turkey.

Authors:  Gülin Renda; Arzu Özel; Burak Barut; Büşra Korkmaz; Nurettin Yayli
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.